Previously doing business as American Stem Cell Inc., Targazyme, Inc., a clinical-stage biopharmaceutical company, is engaged in developing and commercializing technologies and products that improve cell-based therapies and immunotherapies across a range of indications. With facailites in Texas and in Switerland, Targazyme offers ASC-101, a product for stem cell transplantation for hematological malignancies and for cell therapies of other cancer indications, as well as for ischemic diseases; ASC-102, a product for immune cell treatment for cancers; and Extracellular superoxide dismutase, an enzyme that destroys free radicals. The company's products applications include hematopoietic stem cell transplants, immunotherapies for solid tumors, cell therapies to ameliorate graft-versus-host and autoimmune diseases, and cell therapies for ischemic diseases, such as myocardial infarction and stroke. The company is based in Carlsbad, California with additional offices in San Diego, California; and Basel, Switzerland
